New drug targets Hard-to-Treat prostate cancer in early trial
NCT ID NCT04702737
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 26 times
Summary
This early-stage study tested a new drug, Tarlatamab, in 41 men with a rare and aggressive form of prostate cancer called neuroendocrine prostate cancer. The main goal was to check the drug's safety and find the best dose. The drug works by helping the body's immune cells attack cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chris OBrien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
Community Health Network MD Anderson Cancer Center - North
Indianapolis, Indiana, 46250, United States
-
Erasmus Medisch Centrum
Rotterdam, 3015 GD, Netherlands
-
Gustave Roussy
Villejuif, 94805, France
-
Hospital Clinic i Provincial de Barcelona
Barcelona, Catalonia, 08036, Spain
-
Keio University Hospital
Shinjuku-ku, Tokyo, 160-8582, Japan
-
Landeskrankenhaus Salzburg
Salzburg, 5020, Austria
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Medizinische Universitaet Graz
Graz, 8036, Austria
-
Ordensklinikum Linz Elisabethinen
Linz, 4020, Austria
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Royal Marsden Hospital
Sutton, SM2 5PT, United Kingdom
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
University of California at San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27103, United States
-
Washington University
St Louis, Missouri, 63110-1093, United States
-
Weill Cornell Medical College
New York, New York, 10021, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.